Stomach Cancer Drugs Market Dynamics, Comprehensive Analysis, Business Growth, Prospects and Opportunities by 2026 Appraised By Global Players Pfizer Inc., Eli Lilly and Company, GlaxoSmithKline Plc., Kuhnil Pharmaceutical Co. Ltd.

Stomach cancer is the fifth most common cancer globally regardless of gender as reported by the World Cancer Research Fund (WCRF) in 2018. There are many factors which cause stomach cancer such as unhealthy diet, smoking, obesity, alcohol, and Helicobacter pylori infection. According to the Cancer Research U.K. data of 2016, one out of three stomach cancer cases is related to Helicobacter pylori infection in the U.K. annually. Stomach cancer tests identify the stage of the cancer and the patient is treated accordingly. Targeted drug therapies are frequently used to treat stomach cancer as these drugs target the rapidly dividing cells and have less side effects. Drugs that target HER2 are under developmental studies to treat advanced stomach cancer. For instance, pertuzumab in combination with trastuzumab and chemotherapy is under phase 3 clinical trials to treat metastatic gastroesophageal junction or gastric cancer.

Download PDF Brochure Of This Research Report @ https://www.coherentmarketinsights.com/insight/request-pdf/2667

Market Dynamics

Increasing prevalence of stomach cancer worldwide is expected to boost the stomach cancer drugs market size. For instance, according to WCRF data of 2018, around one million cases of stomach cancer were diagnosed in 2018. Furthermore, increasing geriatric population is at a high risk of developing stomach cancer and men are more vulnerable to developing stomach cancer. For instance, according to the American Cancer Society (ACS) report in 2014, the average age of people diagnosed with stomach cancer is 68. As per the same source, six out of ten people diagnosed with stomach cancer annually are 65 or older, and stomach cancer is the fourth most common cancer in men.

However, the major challenge in the stomach cancer drugs market are the high expenses related to treatment of stomach cancer, which are not affordable to the middle to low income families in most countries. According to a data published in Oncotarget (impact journal) in 2017, the cost of stomach cancer drugs (considering Trastuzumab) can reach up to US$ 8,000 for four weeks and annually it can reach up to US$ 96,000.

Increasing FDA approvals of biosimilars for treatment of stomach cancer is expected to drive growth of the stomach cancer drugs market

The stomach cancer drugs market revenue is expected to increase, owing to increasing number of FDA approvals for biosimilars. Adoption of biosimilars in last five years is on a high demand because of the comparatively lower price than biologics treatment of stomach cancer. For instance, in 2017 Biocon Ltd., in partnership with Mylan N.V., received FDA approval for Ogivri (trastuzumab) for the treatment of stomach cancer or gastro-esophageal junction adenocarcinoma. Ogivri is the first FDA-approved biosimilar of Herceptin and the first biosimilar from Mylan and Biocon’s joint portfolio approved in the U.S. Further, In March 2019, Pfizer Inc. announced the U.S. Food and Drug Administration (FDA) approval of TRAZIMERA (trastuzumab), a biosimilar of Herceptin (trastuzumab), for the treatment of HER2 overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma.

Moreover, the reimbursement policies for stomach cancer drugs are highly contributing to the stomach cancer drugs market growth. There are government and private healthcare policies which reimburse the charges of stomach cancer drugs which also increases the adoption of drugs because of reimbursement policies. For instance, according to Bristol-Meyer Squibb Medicare Part B will reimburse 80% of the price of Opdivo and remaining 20% is patient’s responsibility. Opdivo is under clinical trial in phase 3 for treatment of stomach cancer.

Inquire Here Before Purchase of Research Report @ https://www.coherentmarketinsights.com/insight/talk-to-analyst/2667

Stomach Cancer Drugs Market - Restraints

The major restraining factors for growth of the stomach cancer drugs market are the serious side effects caused by the drugs. These include nausea and vomiting, loss of appetite and weight loss, fatigue, diarrhoea, hair loss, sore mouth, hand-foot syndrome, low blood cell counts, blood clots (Deep Vein Thrombosis), nervous system damage, and heart damage in patients undergoing treatment for stomach cancer. According to the 2017, report of the American Cancer Society (ACS) on side effects of stomach cancer, chemotherapy drugs such as doxorubicin and epirubicin can cause permanent damage to the heart if used for a long time or in high doses. As per the same source, other drugs such as Cisplatin, oxaliplatin, docetaxel, and paclitaxel can cause major damage to nerves outside the brain and spinal cord.

Stomach Cancer Drugs Market - Regional Insights

On the basis of region, the global stomach cancer drugs market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America is expected to hold a dominant position in the global stomach cancer drugs market during the forecast period owing to rising number of clinical trials for drug development for treatment of stomach cancer. For instance, Bristol-Myers Squibb in 2016, initiated a clinical study to test combination treatments for stomach cancer. A comparative study between Nivolumab in combination with other therapies and Nivolumab in combination with Ipilimumab to check which therapy is more effective in treating patients with advanced stomach cancer. In February 2019, the study entered in phase 2 and it is estimated to be completed in 2021.

Asia Pacific is expected to foresee a rapid growth in the stomach cancer drugs market, owing to a rise in launch of biosimilars for treating stomach cancer. For instance, in 2018, Dr. Reddy’s Laboratories launched Hervycta trastuzumab (Herceptin biosimilar) in India. Dr. Reddy’s Laboratories who also developed the biosimilar, said that the drug will be sold under the name Hervycta and it will be used in the treatment of metastatic gastric cancer. Biosimilar trastuzumab is Dr. Reddy’s 4th biosimilar to be commercialized in India and in various other emerging markets.

Stomach Cancer Drugs Market - Competitive Landscape

Key players operating in the global stomach cancer drugs market include Pfizer Inc., Eli Lilly and Company, GlaxoSmithKline Plc., Kuhnil Pharmaceutical Co. Ltd., Daiichi Sankyo Co. Ltd., Merck KGaA, AstraZeneca Plc, Otsuka Holdings Co. Ltd., Sanofi S.A., and F. Hoffmann-La Roche Ltd, Ono Pharmaceutical Co. Ltd., Bristol-Myers Squibb (BMS), Jiangsu HengRui Medicine Co. Ltd., Gilead Science Inc., Celgene Corporation, Taiho Pharmaceutical, Boston Biomedical Inc., and Merck & Co.

Contact Us

Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com

About Coherent Market Insights

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

This release was published on openPR.